English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
When a Trip Goes Sideways: What to Do When a Friend Has a Bad Psychedelic Experience
Someone you love takes a psychedelic. Maybe mushrooms at a music festival. Maybe ayahuasca at a retreat you both saved for months to attend. Maybe LSD in a friend's living room on a Saturday night. And somewhere along the way, the trip turns. Their eyes go glassy in a way that isn't wonder anymore. They start repeating a sentence. They curl up. They cry, or they get scared, or they get quiet in a way that makes the room feel colder. What now? This is the question nobody wants to think about before they head off to a ceremony or a festival — and it's the exact question everyone eventually needs to answer. The world of ayahuasca, psychedelics, and master plants isn't all sunrise meditations and breakthrough insights. Sometimes the medicine drags people through territory they weren't ready for. Sometimes a friend goes somewhere hard, and you're the one sitting next to them, watching it unfold, wondering if you're helping or making it worse. Here's what I've learned from sitting in ceremony spaces, from talking with facilitators who've seen it all, and from being the friend on both sides of that hard moment. First, let's ditch the phrase “bad trip.” It's lazy shorthand that lumps together very different experiences — a moment of anxiety, a confrontation with old trauma, a full-blown dissociative crisis. These aren't the same thing, and they don't need the same response. A difficult experience might look like intense fear or paranoia, uncontrollable crying, repetitive movements, feeling trapped in a loop, dissociation from the body, or the conviction that something terrible is happening or has already happened. Sometimes it looks calm on the outside — the person is simply gone, eyes far away, unreachable for a while. None of these are automatically emergencies. Psychedelic states are wildly nonlinear. A person can move from terror to peace to laughter in the space of twenty minutes. The trap most sitters fall into is treating every hard moment like a crisis, when what's actually happening is a healthy — if unpleasant — unfolding. Hard is: crying, shaking, expressing fear, saying things that don't make sense, wanting to be held or left alone, purging on ayahuasca (which is often part of the process), reliving something old. Dangerous is: trying to run into traffic, wanting to hurt themselves or someone else, showing signs of a serotonin or cardiac emergency, having a seizure, taking additional substances mid-experience, or losing consciousness in a way that doesn't fit the substance's normal profile. Dangerous means you call for help, no ego involved. The single most useful thing you can do is regulate your own nervous system. Psychedelic states are famously permeable — the person tripping is picking up on everything around them, including whether you're panicking. If you're calm, they have something to co-regulate with. If you're spiraling, you're pouring gasoline on their fire. Breathe slowly. Sit at their level, not looming over them. Keep your voice low and unhurried. Don't crowd them, but don't disappear either. Your job is to be a steady, unspectacular presence — a lighthouse, not a rescue helicopter. A few practical things that tend to help: The old advice from the Zendo Project — the harm-reduction group that has sat with thousands of people in altered states — boils down to four principles: create a safe space, sit, don't guide; talk through, not down; and difficult is not the same as bad. Those four have never failed me. Ayahuasca deserves its own paragraph here because the difficult moments in a ceremony can look extra alarming to anyone who hasn't seen them before. People purge — sometimes for hours. People wail. People say things in languages they don't speak. People appear to fight invisible things. To an outsider it can look like a horror film. To an experienced facilitator, most of it is just Tuesday. This is one of the strongest arguments for choosing a legitimate retreat with real Amazonian lineage rather than a rented Airbnb and a stranger with a jar of brew. In a proper ceremony, a curandero or curandera is reading the room constantly. They know the songs — the icaros — that can steady someone spinning out. They know when to sit closer, when to sing louder, when to move a person to a different spot in the maloca. That skill isn't decorative. It's the difference between a hard night that becomes medicine and a hard night that becomes trauma. If you're considering a ceremony and worried about the difficult scenarios, the honest answer is: don't go alone, and don't go cheap. Ask retreat centers directly what their protocols are for someone in acute distress. A reputable place will have a clear answer. A sketchy one will get defensive. Here's the part almost nobody prepares for. The trip ends. Your friend is exhausted, quiet, maybe embarrassed, maybe blank. The temptation is to move on — make breakfast, laugh it off, pretend the strange night didn't happen. Don't. The 72 hours after a difficult psychedelic experience are the most important stretch of the whole thing. This is when the raw material either gets metabolized into insight or gets stuffed into a box that will rattle for years. What people who've done real healing work with plant medicine and psychedelics for addiction, depression, or trauma will tell you — almost universally — is that the medicine cracks something open, and integration is what turns that opening into change. Some things that help during integration: If the experience surfaced something the person is genuinely struggling with — flashbacks, persistent anxiety, intrusive imagery lasting more than a few weeks — that's a signal to work with a professional, not to tough it out. Most cities now have therapists who specialize in psychedelic integration. They exist because this need is real and increasingly common. None of what I've written should scare you off. Difficult moments are part of the territory, and the vast majority of them are exactly where the healing lives. The people I know who credit ayahuasca or psilocybin with pulling them out of addiction, depression, or a long stuck patch almost always tell the same story: it wasn't the pretty visions that changed them. It was the night they thought they were dying, and the moment on the other side of it. What matters is the container. Who is holding the space. Whether there's someone there who's seen a hundred hard nights and knows the difference between a soul working itself out and a body in trouble. Whether integration is built into the program or you're on your own the moment you land back home. Ask hard questions before you book. Talk to past participants. Read reviews with a suspicious eye — anywhere with only glowing five-star reviews is either brand-new or curating heavily. If you can, talk to the facilitator directly before committing. Trust your gut. The right retreat feels grounded, not glamorous. For readers who want to take this further, a range of vetted ayahuasca and psychedelic retreats can be browsed on our marketplace here. Wherever you end up, may your difficult moments — the ones you have and the ones you sit with for others — turn into the kind of medicine that actually changes something.
Extreme Fear on 5-MeO-DMT: What It Means and How to Move Through It
There's a moment, roughly fifteen seconds after the vapor hits the lungs, when some people encounter something that words don't really cover. Not a bad trip in the classic sense. Not visuals melting into visuals. Something more like being shoved off the edge of everything you thought you were, with no handrail and no warning. Fear on 5-MeO-DMT — the psychedelic secretion from the Sonoran Desert toad, sometimes called bufo — can be absolute. And it's one of the least discussed corners of the whole plant medicine conversation. If you've been researching a bufo ceremony, or you've already had one and you're still shaken by what happened, this is for you. Not a sales pitch. Not mysticism dressed up in modern clothes. Just what I've seen, what facilitators have told me, and what the people who've been through it tend to wish they'd known first. People who've done ayahuasca, psilocybin, LSD, even smoked N,N-DMT often walk into a 5-MeO ceremony thinking they know the territory. They don't. The two DMTs share three letters and almost nothing else experientially. Ayahuasca unfolds over hours, gives you room to negotiate, lets you sit with imagery and memory. 5-MeO strips the negotiation table away. In the reports I trust most, there is no self left to negotiate with. That's the point. And that's also what makes it terrifying for a not-insignificant number of participants. The onset is fast — under a minute — and the peak arrives before your body has caught up with the fact that anything is happening. Some people describe it as a kind of white light or oceanic dissolution. Others describe pure, wordless panic. Both are considered normal reactions in the underground and clinical communities that work with the medicine. The problem is that most retreat marketing shows you the first version and skips over the second. The fear on 5-MeO isn't usually the same as a difficult mushroom trip, where a scary thought loops and you can talk yourself down. It's more like the fear of ceasing to exist — because in some sense, for a few minutes, you kind of are. Ego death sounds poetic in a podcast. Lived from the inside, it can feel like dying. Your body may thrash, freeze, moan, or go completely still. You may believe, in that moment, that you will never come back. You always do. But no article can convince a nervous system mid-experience of that. Here's the honest answer: a strong fear response on 5-MeO-DMT is common enough that experienced facilitators plan for it. It doesn't mean you got a bad batch, a bad ceremony, or that you're psychologically broken. It usually means one of a few things. Any one of those is enough. Two or three together and terror becomes almost predictable. The medicine itself isn't punishing you. It's showing you the location of the resistance with extraordinary precision. Studies on 5-MeO-DMT are still thin compared to psilocybin or MDMA, but survey data from Johns Hopkins and other groups suggests that a meaningful minority of participants report challenging experiences — including fear, panic, and lingering psychological difficulty in the days after. Most also report significant reductions in depression and anxiety weeks later. Both things can be true. The medicine can hand you the worst hour of your life and, months later, you may say it was one of the most important. I'm not romanticizing that. I'm telling you what the data and the interviews consistently show. People often ask what they can actually do to reduce the odds of a terrifying journey. The truthful answer is: a lot, but not everything. You don't control the medicine. You control the container you bring to it. Preparation for 5-MeO isn't the same as prepping for ayahuasca. You're not doing weeks of dieta with master plants. You're doing something more like preparing for a very intense meditation retreat compressed into fifteen minutes. That means nervous system work, not just intention-setting worksheets. The people I've interviewed who report the smoothest journeys almost always share one trait: they had done meaningful work on their nervous system before the ceremony, not just their mindset. Belief that you're ready is not the same as being ready. If you're reading this because something happened and you're still rattled — days, weeks, or months later — please know that integration matters more than the experience itself. The 5-MeO community has gotten better at this, but it's still uneven. Some retreat centers send you home the next morning with a hug and a smoothie. That's not enough. Real integration after a fear-heavy 5-MeO experience usually involves: If you're experiencing lingering symptoms — dissociation, persistent anxiety, intrusive re-experiencing — treat it seriously. It's rare, but it happens, and it's not shameful. It's a medical situation that deserves proper support. This is where the retreat you pick matters most. A skilled 5-MeO facilitator has sat with hundreds of people, many of them terrified, and knows how to stay grounded while someone else's world dissolves. You want someone who has training in psychological first aid, who works with a small group or one-on-one, who doesn't push higher doses, and who has integration support built into the offering — not tacked on as an upsell. Questions worth asking before you book anything: If the answers are vague, or you're being sold on transformation before safety, keep looking. There are careful, experienced practitioners in this space, and there are people who found out about bufo eighteen months ago and started charging for ceremonies. The gap between them is enormous. Here's the part that took me a while to accept. Fear on 5-MeO-DMT isn't a sign that psychedelic healing failed you. Fear is often the material. The medicine is showing you where you're bracing against your own life, and it's doing it at a speed the mind can't manage. Whether that becomes a breakthrough or a wound depends less on the substance and more on what surrounds it — the facilitator, the setting, the preparation, the integration. Plenty of people who had terrifying first experiences with bufo have gone on to describe it as pivotal. Others have decided, sensibly, that this particular medicine isn't for them, and moved toward slower work with ayahuasca, psilocybin, or non-psychedelic approaches. Both choices are valid. The one choice that isn't valid is going in blind because a friend said it changed their life. For readers who want to keep exploring this carefully, a range of vetted 5-MeO-DMT and broader plant medicine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine will still be there when you're actually ready.
Psychedelics and Contemplative Practice: Where Plant Medicine Meets Meditation
There's a question that keeps circling back in the plant medicine world, and it's not going away. Can psychedelics and contemplative practice actually work together, or are they two different paths pretending to share a map? Anyone who's sat in an ayahuasca ceremony after years of meditation — or tried to meditate the week after one — knows this isn't a theoretical question. It's a lived one. The conversation around psychedelics, master plants, and consciousness has moved a long way from the fringes. Clinical trials are looking at psilocybin for depression. Ibogaine clinics are quietly pulling people out of decades of addiction. Ayahuasca retreats are booked six months out. And running underneath all of it is a much older current: the contemplative traditions that have been mapping inner experience for thousands of years without any chemical help at all. If you're reading this, you're probably somewhere in the middle of a decision. Maybe you've meditated for years and you're wondering whether a psychedelic retreat would open something the cushion hasn't. Maybe you've had a big ayahuasca experience and you can't figure out how to hold it — how to bring it into a Tuesday afternoon. Either way, the two worlds are asking the same underlying question: what is this mind, and what happens when it lets go of its usual grip? The interesting thing is that until recently these two communities barely spoke to each other. Meditators treated psychedelics as a shortcut, or worse, a cheat. Psychedelic enthusiasts treated meditation as slow and dry. Both were half right and half missing the point. What's happening now — in retreats, in research, in living rooms — is that people are actually comparing notes. Sit with a serious meditator for long enough and they'll describe states that sound uncannily like a moderate psychedelic experience. Dissolution of self. Time going strange. A sense that consciousness is not a private little thing inside a skull but something wider, thinner, more shared. Sit with someone who's done ten ayahuasca ceremonies and they'll describe insights that any Zen teacher would nod at. The territory looks similar. The vehicles differ. Here's the thing that took me years to notice: the plant medicine tradition and the contemplative tradition are pointing at the same territory from opposite directions. Contemplative practice is slow, patient, cumulative. It builds a stable platform. Psychedelics — ayahuasca, psilocybin, San Pedro, ibogaine — crack the door open faster and wider, but they don't necessarily give you the muscle to stay in the room. Which is why so many facilitators now recommend some form of contemplative practice alongside plant medicine work. Not because meditation makes ceremony more spiritual (that's marketing talk), but because it gives you somewhere to put what happens next. In Amazonian shamanism, master plants aren't just pharmacology. They're understood as teachers — individual intelligences that a person diets with, sometimes in isolation, sometimes over years. Ayahuasca is the most famous of them, but there are dozens: chacruna, chiric sanango, ajo sacha, bobinsana, tobacco. Each one is said to teach something different. Bobinsana teaches heart-opening. Tobacco teaches grounding and protection. Ayahuasca teaches, well, ayahuasca teaches whatever it decides you need to see. The concept is strange to a Western mind at first. A plant, teaching? But if you sit with it long enough, something shifts. You start noticing that the encounter isn't quite what you assumed. It's not that the plant is a pharmaceutical that produces effects. It's more that the plant introduces a relationship, and the relationship changes you. This is where the contemplative frame becomes useful. If you approach plant medicine with the same attitude you'd bring to a serious meditation retreat — patience, humility, willingness to sit with discomfort — the experience tends to be more coherent. If you show up looking for a fireworks show, you might get one, but you probably won't be able to metabolize it. Anyone considering plant medicine for addiction is asking a specific version of this question. Can a substance help me get free of substances? The evidence — and I mean both the clinical trials and what long-time facilitators have watched happen in ceremony — increasingly says yes, but with major asterisks. Ibogaine has the strongest track record for opioid addiction. It's an intense, medically-monitored experience, not a retreat weekend, and it can genuinely interrupt withdrawal in ways nothing else does. Ayahuasca has shown promise for alcohol dependence and stimulant addiction, particularly when combined with sustained integration. Psilocybin has been studied for tobacco addiction with encouraging results. But here's what people miss: the substance is the smallest part of it. What actually breaks the addictive pattern is what happens around the experience — the preparation, the container, the group, the therapist or facilitator, and the months of integration afterward. Take away those pieces and you have a chemical event with no scaffolding. Recovery isn't a single ceremony. It's what you build after. Skip any of those and the odds drop fast. This is why the retreat you choose matters far more than the specific medicine. Meditators who go into ayahuasca or psilocybin work often report a surprising thing: the experiences are less overwhelming than they expected. Not because they're less intense, but because the meditator has built a certain equanimity — a willingness to observe strong sensation and strong emotion without flinching. That capacity translates directly. The reverse is also true. People who've had big psychedelic openings often find their meditation practice suddenly makes sense in a new way. What used to feel like boring homework becomes an ongoing exploration of the territory the medicine showed them. The two practices become one practice, split across two speeds. None of this is a rule. Some experienced meditators have chaotic ceremonies. Some first-timers with no practice at all have profoundly grounded ones. But as a general pattern, contemplative background helps. If you're planning a retreat and you have zero meditation experience, starting even a modest daily practice a few months out is one of the highest-leverage things you can do. The psychedelic retreat industry has exploded, and not all of it is trustworthy. Some places are genuinely serious about what they're doing. Others are luxury tourism with a shaman decal. Before you send anyone money, ask specific questions. Red flags include guarantees of specific outcomes, pressure to book immediately, no medical screening at all, and facilitators who talk more about themselves than about the medicine. Trust that instinct if something feels off. There will be another retreat. The part that surprises most first-timers isn't the ceremony. It's the two weeks after. You come home and everything looks slightly different, and no one around you has any framework for what you just went through. This is where people either build on their experience or lose it. Integration is where contemplative practice earns its keep. Twenty minutes of sitting each morning. A journal you actually write in. A therapist who understands non-ordinary states, or at least doesn't pathologize them. A friend or two who's been through their own version. These are the unglamorous ingredients that turn a peak experience into a durable change. If none of that infrastructure is in place when you get home, the insights fade within a month. Not entirely — something usually stays — but the specific, actionable clarity you had at the retreat becomes a memory rather than a way of living. Build the scaffolding before you go, not after. The conversation between psychedelics and contemplative practice is still young. Neither tradition has fully absorbed the other, and honestly, that's probably healthy. They're supposed to remain distinct. But for the person sitting where you're sitting — considering a retreat, wondering if plant medicine could shift something that's been stuck for years — the practical takeaway is simple. Prepare well. Choose carefully. Integrate seriously. Treat the medicine with the same respect you'd bring to any serious teacher. If any of this resonates and you want to see what's actually available, a curated selection of ayahuasca and plant medicine retreats can be browsed on our marketplace here. Take your time with the choice. The right retreat, at the right moment, with the right preparation, can be one of the most meaningful things you ever do — and that's exactly why it's worth being careful about.
Big Pharma Bets on Psychedelics: What the Lilly-AtaiBeckley Deal Means for Retreat-Goers
Something shifted in the psychedelic world this month, and if you've been following plant medicine even loosely, you probably felt the tremor. Eli Lilly — yes, that Lilly, the insulin-and-Ozempic-and-Alzheimer's-drug pharma giant — agreed to acquire AtaiBeckley, a company developing 5-MeO-DMT (sometimes called the God molecule, sometimes bufo, depending on who you're talking to) for up to $3.8 billion. It's the biggest psychedelic acquisition to date. And it comes with a patent standoff, a fresh round of FDA guidance, and a whole lot of quiet nervousness among people who actually sit in ceremony. If you're someone weighing whether to attend an ayahuasca retreat, a psilocybin container, or a traditional bufo ceremony — the kind of person this site is really written for — you might be wondering what any of this corporate maneuvering has to do with you. Fair question. The short answer: quite a lot, actually, and not always in comforting ways. Let's walk through what's happening and why the retreat world is watching so closely. AtaiBeckley is one of the more prominent developers of pharmaceutical-grade 5-MeO-DMT, a short-acting psychedelic traditionally sourced from the secretions of the Sonoran Desert toad and used in intense, brief ceremonies that often last fifteen to thirty minutes. Lilly reportedly did a full sweep of the psychedelic drug development field before pulling the trigger — kicking the tires on private and public players, including candidates like Compass Pathways' COMP360 psilocybin program. Word from people close to the negotiations is that Lilly liked the short duration of 5-MeO-DMT. From a business standpoint, that matters. A treatment that wraps up in half an hour could plug neatly into the same clinic infrastructure that already delivers Spravato (Johnson & Johnson's ketamine-derived depression drug). Longer-acting molecules like psilocybin — which can keep a patient inside a therapeutic session for six or seven hours — apparently gave Lilly's team pause. Whether that was truly a dealbreaker or just a negotiating angle, sources disagree. Other pharma heavyweights, including AbbVie and Johnson & Johnson, reportedly took a look at AtaiBeckley too. The bidding was competitive. That in itself tells you something: the largest pharmaceutical companies on earth are now openly hunting for psychedelic assets. This is no longer a fringe interest. Here's where it gets thorny. GH Research, another company developing a 5-MeO-DMT product, is in an ongoing patent standoff with AtaiBeckley — now, by extension, with Lilly. The core question is who owns the intellectual property around specific formulations of a molecule that Indigenous communities and underground practitioners have used for generations. Patents on psychedelic compounds are one of the more uncomfortable conversations in this space. You can't patent the toad. You can't patent the vine. But you can, apparently, patent a particular synthesis method, a specific delivery mechanism, a crystalline form, or a dosing protocol. Companies have been racing to stake claims for years. Now that pharma money is flowing in seriously, those claims matter more. For anyone thinking about attending a retreat where 5-MeO-DMT, ayahuasca, or synthetic analogs are offered, this legal wrangling is worth understanding. It shapes what medicines will remain broadly accessible, what gets locked behind clinical settings, and how much cultural friction is coming down the line between traditional practice and pharmaceutical distribution. Around the same time as the Lilly deal, the FDA released its finalized guidance for psychedelic drug development. The field's response has been mixed — some welcoming the regulatory clarity, others frustrated that the document treats psychedelic-assisted therapy through the same lens as any other pharmaceutical trial. The tension is real. Psychedelic experiences don't behave like statins. Set, setting, integration, therapist presence, and the participant's own psyche all shape outcomes in ways the standard clinical trial model was not designed to measure. When you compress that complexity into a placebo-controlled framework, something important gets lost. Practitioners and facilitators in the retreat world have been saying this for years. Now that the regulators are formally weighing in, expect the conversation to intensify. Meanwhile, Resilient Pharma is preparing to resubmit its application for MDMA-assisted therapy after last year's setback. If it clears this time, MDMA becomes the first true psychedelic-assisted therapy legally available through prescribed channels in the U.S. That's a big deal — and it's the exact kind of development that could reshape what people expect from psychedelic healing. Here's the honest part. The pharmaceutical model and the retreat model are not the same thing, and they're not going to become the same thing. A Lilly-branded 5-MeO-DMT product delivered in a clinical setting in Indianapolis is a fundamentally different experience from a ceremony with a Shipibo maestro in Peru or a traditional bufo container with a trained facilitator in Mexico. Both may involve the same molecule. Neither is a substitute for the other. What each offers — and what each demands from you — is distinct. The retreat world tends to emphasize: The clinical model, by contrast, offers standardization, regulatory oversight, insurance coverage (eventually), and access for people who would never fly to the Amazon. Both have real value. Both have real limitations. The mistake is thinking one obsoletes the other. If you're in the middle of researching an ayahuasca retreat or a psilocybin container right now, the corporate news probably feels distant. Should it change your decision? Mostly, no. The reasons to attend a plant medicine retreat — genuine curiosity, stuck patterns, unresolved trauma, spiritual searching, addiction recovery — are the same reasons they've always been. A pharmaceutical company writing a check does not change what happens when you drink the brew. What might change, over the next few years, is the broader landscape. Expect to see: If you're serious about doing this work — and I mean actually serious, not just curious — the practical advice hasn't changed. Choose facilitators with real training and real lineage. Prepare properly. Understand your medical and psychiatric history and be honest about it with the retreat team. Plan for integration before you even leave home. Don't treat ceremony as a vacation with a psychoactive centerpiece. Because the Lilly deal is specifically about 5-MeO-DMT, a note on that particular medicine feels warranted. It's often called the most intense psychedelic experience available to humans. That's not marketing copy — participants routinely describe complete ego dissolution within seconds of inhaling. The experience is brief, but the aftershocks can last months. It is not a starter medicine. Anyone who tells you 5-MeO-DMT is a good first psychedelic is either uninformed or selling something. Most reputable facilitators want participants to have prior experience with ayahuasca, psilocybin, or extended meditation practice before entering a bufo ceremony. That's not gatekeeping — it's harm reduction. The reason pharma finds this molecule attractive (short duration, dramatic effect) is exactly what makes it risky when handled casually. Whether the future belongs to Lilly's clinical version, to traditional Sonoran ceremonies, to synthetic analogs, or to some combination remains to be seen. What I'd caution against, either way, is treating any of these as a shortcut. The pharmaceutical industry's growing interest in psychedelics is not a betrayal of the medicine, and it's not a rescue either. It's simply what happens when a formerly underground field enters the mainstream. Some of it will help people who would never otherwise access these tools. Some of it will flatten the deeper dimensions of the experience into a billable procedure. Both things will be true at once. The retreat world, for all its imperfections, still holds space for the parts of this that don't fit inside a clinical trial — the community, the ritual, the encounter with something that feels older than any of us. That's not going away because Eli Lilly signed a term sheet. If anything, the traditional container becomes more distinct, more valuable, as the pharmaceutical version takes shape alongside it. For readers who want to explore the ceremonies and plant-medicine retreats being discussed across this wider shift in the field, a curated selection can be browsed on our marketplace here. Whichever path you end up walking, walk it with your eyes open.
What a 4-Gram Psilocybin Journey Actually Feels Like
Four grams of dried psilocybin mushrooms sits right at the edge of what most people call a heroic dose. It's not quite the ego-dissolving five-gram territory Terence McKenna made famous, but it's well past the point where you can pretend you're still in control of the ride. If you're researching what a serious psilocybin experience actually feels like — maybe because you're considering a retreat, maybe because you're just curious — this is the terrain worth understanding before you commit. I've spent years around plant medicine ceremonies and psychedelic retreats, and I've watched a lot of people walk into their first high-dose mushroom experience thinking they knew what to expect. Most of them didn't. The dose changes everything. What works as a gentle afternoon at two grams becomes something else entirely once you double it. The come-up on four grams doesn't sneak up on you the way a smaller dose might. Somewhere around the 30-minute mark, the room starts breathing. Colors get a little too interested in themselves. That familiar body buzz shows up, but it's louder — a kind of electric hum that makes you want to sit down, then lie down, then close your eyes. Nausea is common at this dose. Some people throw up. In traditional contexts, purging is treated as part of the medicine — the body letting go of what it's been holding. If you're prepared for it, it's manageable. If you're not, it can feel like the trip is going wrong before it's really started. It isn't. It's just starting honestly. By the 60-minute mark, most people at this dose have stopped trying to describe what's happening. There's a moment — every experienced tripper knows it — where you realize the thing you swallowed an hour ago has fully taken the wheel. That surrender is either the hardest part or the whole point, depending on how you meet it. The peak of a four-gram psilocybin trip lasts roughly two hours, though your subjective sense of time will have very little to do with the clock. People commonly report: The confrontational part deserves its own paragraph. At recreational doses, mushrooms are mostly playful. At four grams, they're not really playful anymore. Whatever you've been avoiding tends to show up. That's why people who use psychedelics for healing — for depression, for addiction, for trauma — often gravitate toward these bigger doses. The medicine gets serious when you get serious with it. This is also why setting matters so much more at this level. A four-gram trip in the wrong environment — noisy, unsafe, with people you don't trust — can become genuinely difficult to navigate. In the right environment, with a sitter or facilitator you trust, the same dose can feel like the most important afternoon of your life. Readers researching psychedelic retreats often ask how high-dose psilocybin stacks up against ayahuasca, San Pedro, or ibogaine. They're not the same experience, though they overlap in useful ways. Ayahuasca tends to feel more directed — like there's an intelligence guiding the session, showing you what needs seeing. The visionary content is often more narrative, more imagistic. Mushrooms feel more elemental, more like being dissolved into something rather than shown something. Neither is better. They're different medicines with different personalities. San Pedro (huachuma) is gentler and longer — a day-long walk through your own psyche rather than a plunge. Ibogaine is in another category entirely: much longer, physically demanding, and used almost exclusively in therapeutic contexts for addiction recovery. If you're weighing options for a retreat, the choice usually comes down to what you're bringing to the work and how much intensity you can hold. The research emerging over the past few years has been remarkably consistent: substantial mystical-type experiences correlate with better therapeutic outcomes for depression, addiction, and end-of-life anxiety. Johns Hopkins, NYU, and Imperial College London have all published work pointing in the same direction. And here's the honest part — you don't reliably get those experiences at low doses. You get them at doses like this. That's the reason retreats offering psilocybin work almost always land in the three-to-five-gram range for a primary ceremony. Below that, the medicine tends to stay decorative. Above it, most people don't remember much and integration becomes harder. Four grams is a working dose for actual psychological movement. None of which means you should book something tomorrow. High-dose psilocybin has real contraindications — a personal or family history of psychotic disorders is a serious flag, and interactions with SSRIs, lithium, and certain other medications matter. A reputable retreat will screen for these things. If they don't, that's your first red flag. The tail end of a four-gram trip is often the most quietly beautiful part. Somewhere around hour four, the intensity releases and you're left in what people call the afterglow — a soft, warm, unusually clear state that can last well into the following day. Emotions run close to the surface. Music sounds better than it has in years. You may cry for no obvious reason and it will feel like relief. The real work, though, starts a few days later. This is what facilitators mean when they talk about integration — the slow process of translating what happened during the trip into changes in how you actually live. Without integration, a big psychedelic experience tends to fade into a story you tell at parties. With it, the experience becomes something that reshapes your life in the months and years afterward. Practical integration looks less mystical than people expect. It's journaling. It's talking to a therapist who understands psychedelics. It's noticing where your old patterns start creeping back and choosing differently. It's boring, in the best possible way. Only you can answer that. But here are the questions worth sitting with before you decide: The people I've watched benefit most from experiences like this are the ones who arrive with humility rather than expectations. They're not looking for enlightenment. They're looking to be honest with themselves. Mushrooms tend to reward that posture. If you've read this far and something about it feels like a call rather than a curiosity, that's worth paying attention to. For readers who want to explore this further in a supported setting, a range of vetted psilocybin retreats can be browsed on our marketplace here. Take your time with the decision. The medicine will still be there when you're ready.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Eli Lilly Buys AtaiBeckley for $3.8B: What It Means for 5-MeO-DMT and Psychedelic Medicine
Something significant just happened in the psychedelic world, and if you're someone who's been quietly researching plant medicine — maybe eyeing a 5-MeO-DMT retreat, maybe wondering whether the whole field is about to change — you should know about it. Eli Lilly, the largest pharmaceutical company on the planet, has agreed to acquire AtaiBeckley for as much as $3.8 billion. That's not a typo. Big Pharma has officially placed its biggest chip on the psychedelics table. AtaiBeckley's lead compound is an intranasal formulation of 5-MeO-DMT — the same molecule found in the venom of the Sonoran Desert toad and in certain plants used ceremonially across South America. Their candidate, BPL-003, is heading into Phase 3 trials for treatment-resistant depression. The deal also includes VLS-01, a DMT-based candidate. And the price tag makes every previous psychedelic acquisition look modest. Lilly is paying $6.75 per share upfront in cash for all outstanding shares, plus up to $2.50 per share in milestone payments tied to development and regulatory approval. Do the math and you get roughly $2.8 billion in cash on day one, with another billion or so in potential milestone-based payouts depending on how things unfold in the clinic and at the FDA. The milestones are structured like this: a payout when VLS-01 hits Phase 3, another when BPL-003 secures FDA approval and DEA rescheduling, and a third when VLS-01 does the same. Each has a time limit — four, five, and seven years respectively. Miss the window, no bonus. To put the scale in perspective: earlier this year Otsuka acquired Transcend Therapeutics for up to $1.225 billion. Late last year, AbbVie picked up Gilgamesh's bretisilocin program for up to $1.2 billion. The AtaiBeckley deal is roughly three times the size of either. It's the largest psychedelic buyout ever, and it's not close. You might be thinking: cool, big finance news, but I'm trying to decide whether to sit in ceremony in Mexico next spring. What does a pharma deal have to do with me? More than you'd think. When a company like Lilly moves in, a few things start happening in parallel. Clinical trials accelerate. Regulatory conversations get serious. Insurance-covered psychedelic-assisted therapy inches closer to reality in the United States. And — this is the part that matters most for the retreat world — the cultural conversation shifts. Substances that were considered fringe five years ago start showing up in mainstream psychiatric discussions. That has knock-on effects for legality, for public perception, and eventually for how easy or hard it is to legally access these experiences. There's also a quieter effect. As pharma standardises dosing, formulation, and clinical protocols, some seekers will still want the traditional container — the shaman, the maloca, the icaros, the community — that no clinic can replicate. Others will prefer the medicalised route. Both paths are widening. The retreat world isn't going away; it's about to sit alongside a very different offering. Since Lilly's press release conspicuously avoided the word "psychedelic" (which tells you something about how the messaging will be shaped going forward), let's be plain about what this molecule is. 5-MeO-DMT is a naturally occurring tryptamine. It's found in the parotid gland secretions of the Bufo alvarius toad, in the bark of certain Amazonian trees, and in the seeds of Anadenanthera plants used in traditional Yopo snuff. In ceremonial contexts, it's often called "the God molecule" — not because anyone's making a theological claim, but because participants routinely describe experiences of ego dissolution and unity so total that ordinary language fails. The experience is short. Typically five to twenty minutes at peak, compared to ayahuasca's four to six hours. But short doesn't mean easy. 5-MeO-DMT is often described as more intense than any other psychedelic, and it demands rigorous preparation, skilled facilitation, and thoughtful integration afterward. This isn't a substance to approach casually or alone. The response within the psychedelic community has been split, and honestly, that's how it should be. This kind of deal is genuinely double-edged. If you're actively researching a psychedelic retreat, here's the honest read. Nothing about today's news changes what you're weighing this week. 5-MeO-DMT retreats — most of them working with synthetic material rather than toad secretions these days, for ethical and ecological reasons — still operate in the same legal gray zones they always have. Same with ayahuasca, psilocybin, and ibogaine retreats. What might shift over the next three to five years is the broader landscape. Expect more clinical trials recruiting participants. Expect more state-level regulatory experiments (Oregon and Colorado are already there for psilocybin). Expect more mainstream media coverage that alternates between breathless enthusiasm and moral panic — often in the same publication. For the individual decision you're making right now, the fundamentals haven't changed. If you're considering plant medicine for depression, addiction, trauma, or a stuck life pattern, the questions to ask a retreat are the same ones that mattered last year: A pharma acquisition doesn't answer any of these. Only the retreat can. Zoom out for a moment. Twenty years ago, the idea that a compound like 5-MeO-DMT would be entering Phase 3 trials backed by Eli Lilly would have sounded absurd. Ten years ago, MAPS was still fighting for MDMA to be taken seriously. Today, the mainstream psychiatric establishment is quietly rearranging itself around psychedelic-assisted therapy. None of this means the medicalised path is the right one for everyone. Plenty of people find deeper healing in a traditional ceremonial setting than they ever would in a clinical suite with fluorescent lighting and a clipboard. The master plants — ayahuasca, San Pedro, iboga, psilocybin mushrooms, and yes, 5-MeO-DMT when treated with appropriate reverence — have been teaching humans about themselves for thousands of years, and they'll keep doing so regardless of what happens on the Nasdaq. But it's fair to acknowledge that we're living through a genuine turning point. The question isn't whether psychedelic medicine will become part of mainstream mental health care — it's how, on what terms, and who benefits. Deals like this one shape those answers. If you've been sitting with the question of whether a retreat is right for you, this news is neither a green light nor a red one. It's context. Take it in, keep researching, and trust your own timing. For readers who want to explore what's actually available right now, a curated selection of 5-MeO-DMT, ayahuasca, and other plant-medicine retreats can be browsed on our marketplace here.
What Psychedelics Actually Feel Like: An Honest Look Inside the Experience
Ask ten people what a psychedelic trip feels like and you’ll get ten wildly different answers. Some talk about geometric visuals dancing behind their eyelids. Others describe crying for three hours over something their father said in 1997. A few just shrug and say, “I felt like myself, but more.” None of them are lying. That’s the strange thing about psychedelics and ayahuasca — the experience refuses to sit still long enough to be described cleanly. If you’re considering a retreat, you’ve probably already watched the documentaries and read the Reddit threads. And you’ve probably noticed that most of them either oversell the mystical fireworks or underplay how physically strange the whole thing can get. So let’s talk about what actually happens in the body and mind when you drink the brew, eat the mushrooms, or sit down for a San Pedro ceremony. Not the marketing version. The real one. Almost every psychedelic experience begins with a peculiar limbo. You’ve taken the medicine. Nothing’s happening. You start wondering if you got a weak batch, or if you’re somehow immune, or if this is going to be the world’s most expensive nap. Facilitators call this the doubt window, and it’s so common it’s basically a rite of passage. Then, quietly, something shifts. It’s not a curtain being pulled back — it’s more like the room’s volume changing by two clicks. Sounds get a little rounder. Your body feels a bit heavier, or lighter, depending on the medicine. With ayahuasca, most people notice a warmth in the stomach and a metallic taste that just won’t leave. With psilocybin, it’s often a giggly restlessness and a sudden interest in the ceiling. With ibogaine, it’s a low buzzing hum that seems to come from inside your bones. None of this feels dramatic yet. That’s the point. Psychedelics don’t kick down the door — they let themselves in through a window you didn’t know was open. Here’s something people rarely mention: psychedelic experiences are deeply physical. Long before you’re contemplating the nature of the universe, you’re dealing with a body that suddenly feels unfamiliar. With ayahuasca specifically, purging is part of the deal. That means vomiting, sometimes crying, sometimes diarrhea, sometimes shaking. Shamans in the Amazon consider the purge medicinal — the body releasing what the mind has been holding. It’s not pleasant, but participants often report an odd relief afterwards, as if something they didn’t know they were carrying just left the building. If a retreat tells you their ayahuasca doesn’t make anyone purge, be suspicious. That’s not a feature. That’s marketing. Other medicines have their own physical signatures: The physical stuff matters because it’s where the resistance lives. Fighting the body sensations is what turns a difficult trip into a truly bad one. Learning to sink into them — even the uncomfortable ones — is half the work. This is the part that’s hardest to translate. Language was built for the ordinary world, and psychedelic states aren’t ordinary. But a few patterns show up again and again in what people describe after retreats. The first is a loosening of the internal narrator. That constant inner voice — the one running commentary on your day, your worries, your grocery list — gets quieter. Sometimes it goes silent completely. In its place, you notice things you hadn’t noticed in years. The specific texture of a memory. The way a piece of music actually feels rather than just sounds. The fact that you’ve been holding your shoulders up around your ears since roughly 2019. The second is emotional access. Feelings that were locked in a filing cabinet somewhere suddenly walk right into the room. Grief you postponed. Anger you rationalized. Tenderness you thought you’d outgrown. This is why plant medicine work is so often paired with trauma healing and addiction recovery — the medicine doesn’t create these feelings, it just removes the door you’d been holding shut. The third is what people clumsily call “ego dissolution.” At higher doses, the sense of being a distinct self can loosen or, in stronger experiences, vanish. This isn’t as terrifying as it sounds when you’re prepared. Most participants describe it as peaceful, even funny — the realization that the self you’ve been defending so hard your entire life is more of a costume than a fortress. Depends on the medicine and the dose. Ayahuasca visuals are famous for a reason — geometric patterns, jaguars, serpents, city-like structures made of light. But they’re not universal. Plenty of experienced drinkers report mostly emotional or bodily journeys with minimal visual content, especially in earlier ceremonies. Psilocybin tends to produce softer, more organic visuals: breathing walls, faces in wood grain, colors that seem lit from inside. San Pedro is often described as visually gentle but emotionally vast. Ibogaine produces something closer to a waking dream — long, cinematic replays of memory, sometimes decades of your life running in reverse. Here’s the honest bit: if you’re signing up primarily for the visual show, you’ll probably be disappointed. The visuals are wallpaper. The real event is what the visuals are pointing at — a feeling, a memory, a question you’ve been avoiding. A four-to-six-hour ayahuasca ceremony isn’t four to six hours of revelation. There are long stretches where nothing much is happening. You’re lying on a mat. You’re slightly uncomfortable. You’re wondering when the next wave will come, or whether you should get up and go to the bathroom, or whether the person two mats over is okay because they’ve been groaning for a while. These stretches are part of the medicine. They’re where restlessness lives, and restlessness is data. What you fidget about in ceremony is often exactly what you fidget about in life. Facilitators worth their salt won’t rescue you from these moments — they’ll let you sit in them, because sitting is the whole practice. Reading trip reports is fine. Watching documentaries is fine. But nothing prepares you like doing the practical work in the weeks before ceremony. A few things that reliably help: Here’s something the retreat brochures underplay: the trip isn’t the healing. The trip is the diagnostic. The healing happens in the ordinary weeks that follow, when you have to actually apply what you saw. People come back from ayahuasca or psilocybin retreats glowing. Two weeks later, some of them are back to their old patterns because they never did the integration work — journaling, therapy, community, small daily practices. The plant medicine cracked the door open. Walking through it is on you. This is why serious retreats now include integration calls, aftercare groups, and referrals to therapists trained in psychedelic integration. If a retreat you’re looking at doesn’t mention aftercare, that’s worth asking about before you book. The other thing worth saying honestly: not every experience is transformational. Some people have a challenging night and don’t receive obvious insight. Some feel like nothing much happened at all. Both are legitimate outcomes, and both are often followed by unexpected shifts weeks or months later, once the mind has finished digesting whatever it was shown. If any of this resonates and you’re starting to think seriously about a ceremony, a wide range of vetted ayahuasca and plant-medicine retreats can be explored on our marketplace here. Read the descriptions carefully, ask questions before you book, and trust the discomfort of not choosing quickly — that hesitation is part of the preparation too.
Psychedelics and Emotions: What Plant Medicine Actually Does to Feeling
Ask ten people who've sat through an ayahuasca ceremony what it felt like emotionally, and you'll get ten different answers. One will tell you they wept for four hours over a grandmother they hadn't thought about in a decade. Another will describe a bottomless, laughing joy. A third will say they felt nothing at all — until three days later, when they burst into tears at a grocery store checkout. Psychedelics do something strange to emotions, and researchers are only starting to map what. If you're weighing a plant medicine retreat, this matters. The stories you hear online tend to skew toward the extremes — the miraculous breakthrough or the harrowing dark night. The emotional middle, where most of the actual work happens, gets less airtime. So let's talk about what the research and the reports actually suggest about psychedelics and feeling, and what a reasonable person considering ayahuasca, psilocybin, or another master plant should know before they book. Classical psychedelics — ayahuasca, psilocybin, LSD, mescaline, DMT — all touch the serotonin 2A receptor. That's a big part of why they change perception. But the more interesting effect, for people considering these substances therapeutically, is what happens to emotional processing. Brain imaging studies over the past several years have shown that psychedelics reduce activity in the amygdala's fear response while simultaneously increasing connectivity between regions that don't normally talk much. The wall between thought and feeling gets thinner. In practical terms: a memory you've kept at arm's length for twenty years suddenly has full emotional weight again. A resentment you thought you'd worked through turns out to still be sitting in your chest. Grief you never let yourself finish shows up ready to be finished. This is why people describe ceremonies as feeling like decades of therapy compressed into one long night. It's not that the substance gives you new information. It gives you access to feelings that were already there. None of this is guaranteed to be pleasant. That's worth saying plainly. One study on psilocybin found that participants reported both dramatically increased positive emotions AND dramatically increased negative emotions during their sessions — often within the same trip. That squares with what facilitators have been saying for decades. A ceremony isn't emotionally one-directional. You can spend an hour in something close to ecstasy and the next hour convinced you've made a terrible mistake with your life. Here's a rough sketch of what people commonly report, though your experience may look nothing like this: The people who get the most out of a retreat tend to be the ones who don't decide in advance which of these they're hoping for. Going in wanting bliss and getting rage is a setup for disappointment. Going in curious about whatever needs to move usually goes better. The clinical research on psychedelics for mental health has been steady and, in some cases, striking. Psilocybin trials for treatment-resistant depression have produced remission rates that outperform conventional antidepressants in some studies. Ayahuasca has been studied for depression with similar directional results. Ibogaine has decades of anecdotal and clinical evidence behind its use for opioid dependence, and MDMA-assisted therapy showed strong outcomes for PTSD in phase 3 trials. The proposed mechanism, in most cases, comes back to emotions. Depression, trauma, and addiction all involve, in different ways, a stuck relationship to feeling. Depression often looks like emotional blunting — you can't access joy, but you can't fully access grief either, so nothing moves. Trauma looks like feelings frozen in place, associated with memories the nervous system won't stop guarding. Addiction, at least one common reading of it, is what people do to avoid feelings they don't believe they can survive. Psychedelics appear to temporarily loosen these patterns. The emotional gates open. What was stuck starts moving. And in the days and weeks after — this is important — the person has a window to build a different relationship with those feelings before the old patterns re-form. That window is why integration matters so much. Retreats tend to sell the ceremony. The real work is often in the two weeks after. People come home from a well-run ayahuasca retreat and find that everything feels louder for a while — colors, food, other people's moods, their own reactions. Small things that used to slide off make them cry. Old certainties feel less certain. This is normal, and it's temporary, and it's also the exact moment where lasting change either roots or doesn't. Some honest advice for that window: Not every retreat is equipped to hold someone through big emotional weather. Some are, some really aren't. If you're going in with genuine trauma, depression, or addiction history, the venue matters more than the marketing implies. Things worth asking before you send a deposit: How many facilitators are present per participant during ceremony? What's the medical screening process? What happens if someone has a psychiatric crisis mid-ceremony — do they have a plan, or do they wing it? Is there integration support included, or does it end when you get on the plane home? Do they screen out people on SSRIs, lithium, or MAOIs? (If they don't, that's a red flag — those combinations range from ineffective to genuinely dangerous.) A good facilitator will answer these questions patiently and without defensiveness. If someone gets cagey when you ask about medical safety, take it as data. The best retreats treat emotional preparation and post-ceremony support as core to what they offer, not as afterthoughts. Plant medicine is not a shortcut, and anyone selling it as one is either naive or dishonest. It can crack something open that talk therapy has been circling for years. It can give you a felt sense of possibilities your rational mind had ruled out. It can, in the right conditions, meaningfully shift depression, trauma responses, and addictive patterns. What it will not do is exempt you from the ordinary work of building a life. The feelings that come up in ceremony still have to be metabolized in daylight. The insights still have to be tested against your actual relationships, your actual work, your actual habits. People who treat a retreat as the destination often end up disappointed six months later. People who treat it as one useful intervention within a longer commitment to their own honesty tend to be the ones who look back on it as pivotal. If any of this resonates and you'd like to look at options, a curated selection of ayahuasca and plant medicine retreats can be browsed on our marketplace here. Take your time with the decision — the right retreat, at the right moment in your life, is worth more than any bargain you might find rushing into the wrong one.
Psychedelics Go Mainstream: What Lilly's $3.8B Buyout Means for Retreat-Goers
Something shifted in the psychedelics world this month, and if you're the kind of person quietly researching ayahuasca retreats at 1am — you know who you are — it's worth paying attention. Eli Lilly, one of the largest pharmaceutical companies on the planet, just agreed to buy a psychedelic drug developer for up to $3.8 billion. That's not a rounding error. That's a signal. At the same time, the FDA quietly released its final guidance for running clinical trials on psychedelics, scheduled a public meeting for September on how these therapies might actually be rolled out, and a Harvard team landed an $11 million federal grant to study ibogaine for opioid addiction. All in one week. The people who track this space for a living called it the busiest stretch in the field's history. So what does any of that have to do with you, the person weighing whether to fly to Peru, or Costa Rica, or Mexico, to sit in ceremony? More than you'd think. Let's unpack it. Lilly's target is AtaiBeckley, a developer focused on 5-MeO-DMT — the compound extracted from the Sonoran Desert toad, sometimes called bufo. It's a short, extraordinarily intense psychedelic experience, and it's been used ceremonially by underground facilitators for a decade or so. Now it's on track to become a prescription medicine, developed under FDA rules, with clinical trials and manufactured doses. The price tag matters. Up to $3.8 billion is the kind of money that ends debates about whether psychedelics are a passing wellness fad. When Lilly writes a check that size, their board has already decided this is a real category. Investment analysts, insurance companies, and regulators are all taking notes. What it doesn't mean: that your ayahuasca ceremony in the Amazon is about to become a Lilly product. Traditional plant medicines — ayahuasca, San Pedro, iboga, psilocybin mushrooms in their whole form — are unlikely to be patented and sold as pharmaceuticals. What pharma companies pursue are isolated molecules, standardized doses, and treatment protocols that fit inside a clinic visit. Two very different worlds. But those worlds are starting to talk to each other. The agency's final guidance on psychedelic clinical trials sounds boring on paper. It matters a lot in practice. Until recently, researchers running trials on psilocybin, MDMA, or DMT had to guess at what the FDA wanted to see. Now there's an actual document — how to design the studies, how to handle the therapist's role during dosing sessions, how to measure outcomes that involve, say, mystical experiences or ego dissolution. A public meeting on rollout is coming in September. That's the conversation about who prescribes these medicines, what training facilitators need, and how patients might actually access them once approved. If you've been following the MDMA-for-PTSD saga — which hit turbulence when the FDA sent it back for more data — this next phase matters. The regulators are building a road, not just approving a single drug. For someone considering a plant medicine retreat right now, here's the honest read: legal, FDA-approved psychedelic therapy in the U.S. is coming, but slowly, and it will look nothing like a jungle ceremony. It'll happen in a clinic, cost thousands of dollars, likely won't be covered by insurance for years, and won't include the community, the icaros, the dieta, or the shaman. Different medicine, different container, different results. Here's the piece that stopped me in my tracks. The National Institute on Drug Abuse — a federal agency that spent decades treating psychedelics as public enemies — just handed Harvard $11 million to study ibogaine for opioid use disorder. Ibogaine is the alkaloid from the iboga root, used traditionally in Gabon in Bwiti ceremony, and known for something remarkable: it can interrupt opioid dependence in a single dose. Not manage it. Interrupt it. People who've been through ibogaine treatment — usually in Mexico, Costa Rica, or Portugal, since it's Schedule I in the U.S. — often describe the experience as reviewing their entire life in a long, waking dream. Some emerge with cravings gone. Others relapse. It's not a miracle, and it has real cardiac risks that have killed people who weren't properly screened. But the anecdotes have been strong enough, for long enough, that even the federal government wants a rigorous answer. Why this matters for retreat-goers: You could read all this news as reassurance. Governments are studying it, pharma companies are buying it, Harvard is publishing on it — clearly plant medicine works. That's half true and half misleading. Here's the more useful frame. The mainstreaming of psychedelics does three good things for retreat-seekers. First, it raises the floor on safety. As more research comes out, more retreat centers adopt medical screening, integration support, and facilitator training that actually meets a standard. Second, it makes the conversation more honest. Your therapist back home is less likely to look at you sideways when you say you're going to sit with ayahuasca. Third, it opens legal pathways — Oregon and Colorado already have regulated psilocybin programs, and more states will follow. But there are risks in the hype too. Money flowing in attracts opportunists. Retreat centers are opening faster than qualified facilitators are being trained. Marketing has gotten slicker. Prices have climbed. And the temptation to skip the boring parts — the preparation, the dieta, the integration afterward — grows when the whole thing is framed as a product you buy rather than a practice you enter. If you're actively weighing a booking, a few things worth knowing: The news cycle will keep churning. Another pharma acquisition will happen. Another study will drop. Another state will pass a psilocybin bill. None of that changes the essential question a retreat-seeker has to sit with: is this the right medicine, in the right container, at the right moment in your life? If the answer is yes — or even a curious maybe — a range of vetted ayahuasca, psilocybin, and ibogaine retreats can be browsed on our marketplace here. Take your time. The medicine will still be there next month, and the right retreat is worth waiting for.
Ego Dissolution on Psychedelics: What Happens When the Self Dissolves
There's a moment, somewhere deep into a strong psychedelic experience, when the person you thought you were simply isn't there anymore. No voice narrating. No preferences. No sense of where your body ends and the floor begins. People describe it a dozen different ways — becoming a stone buddha, dissolving into the ceiling, watching their name evaporate like steam. It sounds like nonsense until it happens to you. This is what researchers call ego dissolution, and it's one of the most talked-about and least understood features of the psychedelic experience. For anyone weighing an ayahuasca retreat or a psilocybin container, it's worth understanding what this state actually is, why it seems to matter for healing, and what it does not mean. Because when psychedelics get discussed in wellness circles, the phrase “ego death” tends to get thrown around like it's some sort of graduation ceremony. It isn't. It's stranger and quieter than that. Your ego, in this context, has nothing to do with arrogance. It's the ordinary sense of being a discrete self — the narrator behind your eyes, the one who remembers what you had for breakfast and worries about the email you haven't sent. That construction is remarkably load-bearing. It runs almost every waking second of your life. And under a strong enough dose of ayahuasca, psilocybin, or 5-MeO-DMT, that construction can go offline. What replaces it varies. Some people describe becoming a landscape — a mountain, a river, a stone figure sitting perfectly still while the world moves past. Others describe pure awareness with no subject and no object, just a quality of noticing. Still others report merging with a person, an ancestor, or an intelligence they can't name. The common thread is that the usual referent — me — is missing, and yet something is still there, observing, present, alive. Neuroscience has a partial explanation. Imaging studies of people on psilocybin show reduced activity in the default mode network, the set of brain regions associated with self-referential thinking. When that network quiets down, the rigid boundaries of self-concept loosen. Whether that fully explains the subjective experience is another question entirely. The brain scans and the felt experience are not the same map. Here's where it gets interesting for anyone considering plant medicine for depression, trauma, or addiction. A lot of what keeps people stuck is identification with a story. I'm the one who was hurt. I'm the addict. I'm the failure. I'm the person this happened to. Those stories aren't false, exactly, but they're sticky. They organize behavior in ways that keep the pain circulating. When the ego briefly steps aside, the story steps aside too. People report seeing their patterns from the outside, without the usual defensiveness. A person who has spent twenty years explaining why they drink might, for a few hours, simply not be the drinker at all. That gap — that glimpse of a self without the burden — is what many facilitators consider the therapeutic hinge of the experience. It's not magic. It's a rare opportunity for the mind to look at itself without flinching. This is one of the reasons plant medicines like ayahuasca and ibogaine have drawn attention from people struggling with addiction. The research is still early and mostly small-scale, but the mechanism people describe is consistent: a temporary loosening of the identity structure that had made change feel impossible. Master plants, as the Amazonian traditions call them, seem to teach through this loosening rather than through anything cognitive. Descriptions from ceremony are all over the map, but a few motifs come up again and again. People report the sensation of turning to stone — heavy, immovable, but not in a distressing way. Others describe a slow dissolution, like sugar in warm water. Some experience it as terror at first (the ego doesn't love being asked to leave the room), followed by a strange peace once resistance stops. A few things worth knowing: The people who talk about it least, in my experience, are the ones who've been most changed by it. There's a quietness about them. They stop needing to convince anyone of anything. Short answer: no. Long answer: also no, but with more nuance. Contemplative traditions have described states resembling ego dissolution for thousands of years. Buddhism has its language for it. So do Advaita Vedanta, certain Christian mystics, and a scattering of Sufi poets. What those traditions insist on — and what a weekend of psychedelics can't provide — is integration. A monk who touches a similar state after fifteen years of practice has fifteen years of scaffolding to hold what happens next. A person who touches it on their first psilocybin retreat has a plane ride home and a job on Monday. This is why serious facilitators talk so much about integration. The experience is only half the story. What you do with it in the six months after — how you reorganize your habits, your relationships, your work — determines whether it becomes a permanent shift or a memory that fades into a good anecdote. Anyone selling you a single-ceremony transformation is either naive or hoping you are. If you're researching an ayahuasca or psilocybin retreat and this whole territory is why — because you've read about ego dissolution and want to know what's on the other side of yourself — a few honest suggestions. Ego dissolution, when it happens, is not the point. It's a doorway, and doorways aren't destinations. The point is what you carry back through it — a slightly looser hold on the self that hurts, a bit more room for the self that might be possible. That's a modest description of something that can feel enormous in the moment, but modesty is closer to the truth than fireworks. People come back from these experiences and, if they're lucky and honest, they don't become gurus. They become slightly kinder to their families. They quit something they'd been meaning to quit. They cry more easily. They laugh at the same jokes but with less edge. The stone buddha, whatever else it teaches, seems to teach that you don't need to be so armored all the time. If any of this resonates and you're thinking about taking the next step, a range of curated ayahuasca and psilocybin retreats with experienced facilitators can be browsed on our marketplace here. Take your time choosing. This isn't a purchase you rush.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
